FWD Care, Inc. dba FWD
Has FWD Care, Inc. dba FWD received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued FWD Care, Inc. dba FWD a warning letter naming semaglutide and tirzepatide, dated Sep 9, 2025, with the FDA subject line “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth).”
FDA records in this index name FWD Care, Inc. dba FWD on Sep 9, 2025.
- Websites the letters name
- fwd.care (see how each letter refers to them)
- Type named in FDA records
- Telehealth
- FDA warning letters
- 1
- Drug recall reports
- 0
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Sep 9, 2025
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Sep 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Sep 9, 2025: … website offers various compounded drug products, including semaglutide and tirzepatide. As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading … any particular. The following claims concerning compounded semaglutide and tirzepatide products appear on your website: … Full letter
Websites named in the letters
Each letter below is addressed to the firm FDA names in it, not to a website. The sentence quoted is the letter’s own reference to the site, copied from the letter on fda.gov.
- fwd.care: FDA’s warning letter of Sep 9, 2025 is addressed to FWD Care, Inc. dba FWD. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://fwd.care in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.” Full letter
Drug recalls
No openFDA drug recall reports in this index.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.